摘要
目的评价莫沙必利联合阿嗪米特治疗胆汁反流性胃炎(BRG)的疗效及安全性,为BRG用药治疗提供参考。方法选择我院收治的166例BRG患者,按照1:1比例分为试验组和参照组,各83例。参照组接受莫沙必利联合碳酸铝镁治疗,试验组接受莫沙必利联合阿嗪米特治疗,对比两组患者用药4周后的临床疗效,治疗前、后症状评分及用药不良反应发生情况。结果试验组患者治疗总有效率高于参照组(P<0.05)。治疗4周后,两组患者腹痛、腹胀、反酸、恶心呕吐等症状评分明显降低,试验组各项评分低于参照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论莫沙必利联合阿嗪米特治疗BRG总有效率高,患者症状改善明显,具有临床推广价值。
Objective To evaluate the efficacy and safety of mosapride combined with azintamide in the treatment of bile reflux gastritis(BRG),so as to provide a reference for the treatment of BRG.Methods One hundred and sixty-six patients with BRG admitted in our hospital were selected,and divided into experimental group and reference group according to the ratio of 11,with 83 cases in each group.The reference group received mosapride in combination with magnesium aluminum carbonate,and the experimental group received mosapride combined with azintamide.The clinical efficacy,symptom scores before and 4 weeks after treatment and drug adverse reactions were compared between the two groups.Results The total effective rate of the experimental group was higher than that of the reference group(P<0.05).Four weeks after treatment,the scores of abdominal pain,bloating,acid reflux,nausea and vomiting in the two groups significantly decreased,and those in the experimental group were lower than the reference group(P<0.05).There was no significant difference in the total incidence rate of adverse reactions between the two groups(P>0.05).Conclusion Mosapride combined with azintamide in the treatment of BRG has high total effective rate,itcan significantly improve the clinical symptoms,which has promotion value.
作者
武和平
WU He-ping((Gastroenterology Departme nt,No.215 Hospital of Shaanxi Nuclear Industry,Xianyang 712000,China)
出处
《临床医学研究与实践》
2018年第8期12-13,共2页
Clinical Research and Practice
关键词
莫沙必利
阿嗪米特
胆汁反流性胃炎
碳酸铝镁
mosapride
azintamide
bile reflux gastritis
magnesium aluminum carbonate
